London-based Big Picture Bio emerges from stealth with €2.55 million to develop AI-designed cancer drug combinations

Reports from EU-Startups indicate that homeUK-StartupsLondon-based Big Picture Bio emerges from stealth with €2.55 million to develop… HomeUK-StartupsLondon-based Big Picture Bio emerges from stealth with €2.55 million to develop…FundingUK-Startups London-based Big Picture Bio emerges from stealth with €2.55 million to develop AI-designed cancer drug combinations By Rahul Raj September 18, 2026 Share FacebookTwitterWhatsAppLinkedin Big Picture Bio, a London-based BioTech startup developing AI-designed combination therapies for cancer and other complex diseases, has emerged from stealth with a combined funding round of €2.55 million (£2.2 million).The funding comprises a €1.75 million (£1.5 million) pre-Seed round co-led by Kadmos Capital and Exceptional Ventures, alongside €815k (£700k) in non-dilutive support from Innovate UK’s Investor Partnerships Programme.Key players involved: Goldman Sachs Asset Management, Partners Group This development has significant implications for the industry, potentially influencing competitive dynamics, investment patterns, and strategic priorities across the sector. “I had the privilege of working closely with Kerstin and Mark at the very beginning of Deep Science Ventures, and saw first-hand the determination, conviction and sheer resolve they bring to building ambitious, scalable businesses,” said Remy Kesrouani, Managing Partner, Kadmos Capital. Market ImplicationsForward-Looking IndicatorsContinued consolidation expected in the sectorIncreasing focus on digital transformation and innovationGrowing importance of ESG considerations Expert Commentary“I had the privilege of working closely with Kerstin and Mark at the very beginning of Deep Science Ventures, and saw first-hand the determination, conviction and sheer resolve they bring to building ambitious, scalable businesses,” said Remy Kesrouani, Managing Partner, Kadmos Capital. Looking AheadFor complete details on this development, refer to the original report from EU-Startups. Frequently Asked Questions